Does Flexion Therapeutics Inc (NASDAQ:FLXN) Have Gas After Even More Sellers Involved?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Logo

Investors sentiment increased to 1.23 in 2018 Q2. Its up 0.28, from 0.95 in 2018Q1. It is positive, as 19 investors sold Flexion Therapeutics, Inc. shares while 28 reduced holdings. 19 funds opened positions while 39 raised stakes. 34.12 million shares or 1.95% more from 33.47 million shares in 2018Q1 were reported.
131 were accumulated by Us Bank & Trust De. Gam Ag owns 0.17% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 188,700 shares. Artisan Prtn Limited Partnership owns 543,788 shares. Cap holds 0.02% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 2.87M shares. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Parkside State Bank & Tru accumulated 163 shares. Raymond James And Associates, Florida-based fund reported 168,115 shares. New York State Common Retirement Fund invested in 0% or 36,200 shares. Bamco New York holds 0.03% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 226,300 shares. Gilder Gagnon Howe And, a New York-based fund reported 3.45M shares. Jpmorgan Chase & holds 0% or 142,895 shares. Moreover, Stifel Financial has 0% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 13,250 shares. Gru Incorporated holds 0.79% or 317,700 shares. Janney Montgomery Scott Lc holds 24,715 shares. Zweig holds 0.35% in Flexion Therapeutics, Inc. (NASDAQ:FLXN) or 223,007 shares.

Since July 2, 2018, it had 2 buys, and 1 sale for $1.10 million activity. Another trade for 4,000 shares valued at $66,222 was bought by Arkowitz David. On Friday, November 9 Clayman Michael D. bought $85,477 worth of Flexion Therapeutics, Inc. (NASDAQ:FLXN) or 5,000 shares.

The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) registered an increase of 4.41% in short interest. FLXN’s total short interest was 11.08M shares in December as published by FINRA. Its up 4.41% from 10.62 million shares, reported previously. With 494,500 shares average volume, it will take short sellers 22 days to cover their FLXN’s short positions. The short interest to Flexion Therapeutics Inc’s float is 35.35%.

The stock decreased 5.02% or $0.79 during the last trading session, reaching $14.96. About 1.81 million shares traded or 163.09% up from the average. Flexion Therapeutics, Inc. (NASDAQ:FLXN) has declined 6.96% since December 8, 2017 and is downtrending. It has underperformed by 22.58% the S&P500.

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company has market cap of $566.34 million. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. It currently has negative earnings.

More notable recent Flexion Therapeutics, Inc. (NASDAQ:FLXN) news were published by: which released: “Analysts Remain Bullish on Flexion Therapeutics –” on June 12, 2018, also with their article: “Flexion: Waiting And Watching – Seeking Alpha” published on August 22, 2018, published: “Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting – GlobeNewswire” on October 22, 2018. More interesting news about Flexion Therapeutics, Inc. (NASDAQ:FLXN) were released by: and their article: “Flexion Is Flexible With The Data, Rigid With The Price – Seeking Alpha” published on October 17, 2018 as well as‘s news article titled: “Flexion – When Approvals Go Bad – Seeking Alpha” with publication date: October 30, 2017.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.